Our PHenomenal Impact Fund for Global PH Research has searched for projects that are novel and forward-thinking in the field of pulmonary hypertension. This year we are specifically asking for projects that would fall into one of the following categories:
-Diversity and Inclusion in Registries and Clinical Trials
-Unmet Needs in Patients with Pulmonary Hypertension
-Substance Abuse and PAH
-What is PAH Disease Modifying Agent
-Patient Engagement Strategies
-Clinical Trial Design and Improving Data Quality
This is not limited to any PH group, pediatrics, or adult studies. Eventual clinical applicability is expected. As such, this program will provide an opportunity for individuals to affect the quality of medical care and improve the lives of patients with pulmonary hypertension.
This research program was created by Team PHenomenal Hope in 2019, and provides awards of $50,000 to investigators during a 12-month period. This research award does not provide additional indirect costs, and the applicant cannot receive overlap funding. Global applicants are welcome to apply. The awards will be chosen by the Team PHenomenal Hope Award Steering Committee based on scientific merit, originality, feasibility, and/or clinical applicability to the diagnosis and treatment of patients with pulmonary hypertension.
The proposal must be deemed achievable within the one year time frame and within the noted fiscal allocation. Applicants must be in their first seven years post fellowship, however if you are outside of this window, but have reason to believe your proposal otherwise fits our criteria, please contact us using the contact form on this website. Non-MDs are welcome to apply (eg. RN, PharmD).
Letters of intent should be two pages including a CV. Please also include details about your project and findings from your work. Tell us how this will transform the field of PH.
Final proposals should be no more than six pages long with an additional page for budget, budget justification, references, and a letter of support from a mentor, division chief, collaborator, etc. Please note that the $50,000 award does not have associated indirects, given that this is an award intended to support pilot research.
The Steering Committee for the program was selected by the Team PHenomenal Hope Board of Directors and currently has four members: Dr. Hap Farber, Dr. Peter Leary, Dr. Hunter Champion, Dr. Matthew Lammi, and Dr. Greg Elliot
Timeline:
Friday, December 5, 2025 - LOI Submission Opens for the 2026 award
Friday, March 20 - LOI Submission Closes
Friday, March 27 - Finalists Notified
Friday, April 24 - Final Applications Due
Announcement of Award Winner - May 2026
Steering Commitee
Harrison Farber, MD
Dr. Farber is a professor in the Department of Medicine and attends in the Medical Intensive Care Unit and on the Pulmonary Consultation Service at Tufts Medical Center. He also cares for a large number of patients with pulmonary hypertension at Tufts Medical Center.
He attended undergraduate at Duke University and completed his medical degree at George Washington University and his residency at the medical College of Virginia. He completed a fellowship in pulmonary and critical care medicine at Boston University and Boston City Hospital Program. Dr. Farber completed an additional research year at Beth Israel Deaconess Hospital in basic science.
Dr. Farber’s research focuses on endothelial cell biology, in particular, the response of the pulmonary vasculature to injury and genomic and proteomic biomarkers of pulmonary hypertension in pulmonary hypertension associated with scleroderma. He has secured extensive government and private funding and is internationally recognized for clinical, investigative and registry contributions to the field of pulmonary hypertension.
Dr. Farber is Vice President of Team PHenomenal Hope, serves on the Board of Directors, and will be the Chairman of the review committee for these grants.
Hunter Champion, MD
Dr. Hunter Champion serves in the Department of Cardiology at Southern Cardiology in Columbus, GA. In addition to heart failure and pulmonary hypertension, Dr. Champion treats patients with hypertension, coronary artery disease, heart rhythm issues, and valvular disease.
Dr. Champion received his B.S. in Biological Science from Emory University and his MD as well as a PhD in Cardiovascular Pharmacology from Tulane University. After his medical school training, Dr. Champion joined the Osler Housestaff Service of the Johns Hopkins University School of Medicine where he completed his internship and residency. He subsequently completed his training in Cardiovascular Disease, Heart Failure and Transplant Cardiology at Johns Hopkins where he was invited to join the faculty of the Cardiology division as an Assistant Professor in Medicine. From 2005-2009, he directed the Bernard Laboratory for the Study of Cardiovascular Disease. In July 2009, Dr. Champion was recruited to the University of Pittsburgh where he joined the faculty of the Divisions of Pulmonary, Allergy and Critical Care Medicine and the Cardiovascular Institute as an Associate Professor of Medicine where he directed Translational Research for the University of Pittsburgh Vascular Medicine Institute. In addition, he directed the Clinical and Translational Vascular Unit of the University of Pittsburgh.
Dr. Champion is a co-founder of Team PHenomenal Hope along with Dr. George and has served on its Board of Directors.
Dr. Peter Leary
Dr. Matthew Lammi
Dr. Greg Elliot
Dr. Elliott is a clinician-scientist and physician-educator with broad expertise in internal medicine and a specialized focus on pulmonary vascular disease, particularly pulmonary hypertension (PH) and pulmonary embolism. Throughout his career, he has dedicated his work to the care of patients living with PH, the education of patients, families, and healthcare professionals, and advancing research to improve understanding and treatment of the disease.
Dr. Elliott has contributed to several landmark initiatives in the PH field, including serving as an investigator for the NIH Registry of Primary Pulmonary Hypertension and as a steering committee member and investigator for the REVEAL Registry. He also helped organize research efforts at the first meeting of the Pulmonary Hypertension Association, supporting collaboration and innovation within the field. His work has contributed to therapeutic advancements in pulmonary hypertension, including research supporting the development of treatments such as sotatercept.
As a member of the Research Award Steering Committee, Dr. Elliott brings decades of clinical, research, and educational experience dedicated to improving outcomes for individuals living with pulmonary hypertension.
